HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited (HCG.BO) Stock Competitors & Peer Comparison
See (HCG.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCG.BO | ₹584.50 | -1.18% | 82.4B | 432.96 | ₹1.35 | N/A |
| APOLLOHOSP.NS | ₹7,720.50 | +0.36% | 1.1T | 61.44 | ₹125.66 | +0.26% |
| APOLLOHOSP.BO | ₹7,718.60 | +0.33% | 1.1T | 61.46 | ₹125.58 | +0.26% |
| MAXHEALTH.BO | ₹1,086.75 | +0.33% | 1.1T | 74.54 | ₹14.58 | +0.14% |
| MAXHEALTH.NS | ₹1,086.40 | +0.26% | 1.1T | 74.82 | ₹14.52 | +0.14% |
| FORTIS.BO | ₹919.95 | +0.04% | 694.5B | 72.49 | ₹12.69 | +0.11% |
| FORTIS.NS | ₹919.55 | -0.02% | 694.2B | 72.46 | ₹12.69 | +0.11% |
| NH.BO | ₹1,821.45 | -2.52% | 369.9B | 43.83 | ₹41.56 | +0.25% |
| NH.NS | ₹1,821.00 | -2.60% | 369.8B | 47.51 | ₹38.33 | +0.25% |
| ASTERDM.NS | ₹638.00 | -1.25% | 329.8B | 100.16 | ₹6.37 | +0.78% |
Stock Comparison
HCG.BO vs APOLLOHOSP.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, APOLLOHOSP.NS has a market cap of 1.1T. Regarding current trading prices, HCG.BO is priced at ₹584.50, while APOLLOHOSP.NS trades at ₹7,720.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas APOLLOHOSP.NS's P/E ratio is 61.44. In terms of profitability, HCG.BO's ROE is +0.02%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, HCG.BO is more volatile compared to APOLLOHOSP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check APOLLOHOSP.NS's competition here
HCG.BO vs APOLLOHOSP.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, APOLLOHOSP.BO has a market cap of 1.1T. Regarding current trading prices, HCG.BO is priced at ₹584.50, while APOLLOHOSP.BO trades at ₹7,718.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas APOLLOHOSP.BO's P/E ratio is 61.46. In terms of profitability, HCG.BO's ROE is +0.02%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, HCG.BO is more volatile compared to APOLLOHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check APOLLOHOSP.BO's competition here
HCG.BO vs MAXHEALTH.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, MAXHEALTH.BO has a market cap of 1.1T. Regarding current trading prices, HCG.BO is priced at ₹584.50, while MAXHEALTH.BO trades at ₹1,086.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas MAXHEALTH.BO's P/E ratio is 74.54. In terms of profitability, HCG.BO's ROE is +0.02%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, HCG.BO is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check MAXHEALTH.BO's competition here
HCG.BO vs MAXHEALTH.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, MAXHEALTH.NS has a market cap of 1.1T. Regarding current trading prices, HCG.BO is priced at ₹584.50, while MAXHEALTH.NS trades at ₹1,086.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas MAXHEALTH.NS's P/E ratio is 74.82. In terms of profitability, HCG.BO's ROE is +0.02%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, HCG.BO is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check MAXHEALTH.NS's competition here
HCG.BO vs FORTIS.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, FORTIS.BO has a market cap of 694.5B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while FORTIS.BO trades at ₹919.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas FORTIS.BO's P/E ratio is 72.49. In terms of profitability, HCG.BO's ROE is +0.02%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to FORTIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check FORTIS.BO's competition here
HCG.BO vs FORTIS.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, FORTIS.NS has a market cap of 694.2B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while FORTIS.NS trades at ₹919.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas FORTIS.NS's P/E ratio is 72.46. In terms of profitability, HCG.BO's ROE is +0.02%, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, HCG.BO is more volatile compared to FORTIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check FORTIS.NS's competition here
HCG.BO vs NH.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, NH.BO has a market cap of 369.9B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while NH.BO trades at ₹1,821.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas NH.BO's P/E ratio is 43.83. In terms of profitability, HCG.BO's ROE is +0.02%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, HCG.BO is less volatile compared to NH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check NH.BO's competition here
HCG.BO vs NH.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, NH.NS has a market cap of 369.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while NH.NS trades at ₹1,821.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas NH.NS's P/E ratio is 47.51. In terms of profitability, HCG.BO's ROE is +0.02%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, HCG.BO is less volatile compared to NH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check NH.NS's competition here
HCG.BO vs ASTERDM.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, ASTERDM.NS has a market cap of 329.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while ASTERDM.NS trades at ₹638.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas ASTERDM.NS's P/E ratio is 100.16. In terms of profitability, HCG.BO's ROE is +0.02%, compared to ASTERDM.NS's ROE of +0.09%. Regarding short-term risk, HCG.BO is less volatile compared to ASTERDM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ASTERDM.NS's competition here
HCG.BO vs ASTERDM.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, ASTERDM.BO has a market cap of 329.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while ASTERDM.BO trades at ₹637.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas ASTERDM.BO's P/E ratio is 100.15. In terms of profitability, HCG.BO's ROE is +0.02%, compared to ASTERDM.BO's ROE of +0.09%. Regarding short-term risk, HCG.BO is less volatile compared to ASTERDM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ASTERDM.BO's competition here
HCG.BO vs MEDANTA.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, MEDANTA.NS has a market cap of 309.1B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while MEDANTA.NS trades at ₹1,149.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas MEDANTA.NS's P/E ratio is 60.20. In terms of profitability, HCG.BO's ROE is +0.02%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to MEDANTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MEDANTA.NS's competition here
HCG.BO vs MEDANTA.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, MEDANTA.BO has a market cap of 309B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while MEDANTA.BO trades at ₹1,150.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas MEDANTA.BO's P/E ratio is 60.22. In terms of profitability, HCG.BO's ROE is +0.02%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, HCG.BO is more volatile compared to MEDANTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check MEDANTA.BO's competition here
HCG.BO vs KIMS.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, KIMS.NS has a market cap of 294.4B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while KIMS.NS trades at ₹735.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas KIMS.NS's P/E ratio is 98.38. In terms of profitability, HCG.BO's ROE is +0.02%, compared to KIMS.NS's ROE of +0.13%. Regarding short-term risk, HCG.BO is less volatile compared to KIMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KIMS.NS's competition here
HCG.BO vs KIMS.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, KIMS.BO has a market cap of 293.5B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while KIMS.BO trades at ₹733.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas KIMS.BO's P/E ratio is 97.92. In terms of profitability, HCG.BO's ROE is +0.02%, compared to KIMS.BO's ROE of +0.13%. Regarding short-term risk, HCG.BO is less volatile compared to KIMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KIMS.BO's competition here
HCG.BO vs RAINBOW.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, RAINBOW.NS has a market cap of 121.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while RAINBOW.NS trades at ₹1,199.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas RAINBOW.NS's P/E ratio is 47.47. In terms of profitability, HCG.BO's ROE is +0.02%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, HCG.BO is less volatile compared to RAINBOW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check RAINBOW.NS's competition here
HCG.BO vs RAINBOW.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, RAINBOW.BO has a market cap of 121.6B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while RAINBOW.BO trades at ₹1,197.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas RAINBOW.BO's P/E ratio is 47.44. In terms of profitability, HCG.BO's ROE is +0.02%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, HCG.BO is less volatile compared to RAINBOW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check RAINBOW.BO's competition here
HCG.BO vs JLHL.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, JLHL.NS has a market cap of 84.2B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while JLHL.NS trades at ₹1,284.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas JLHL.NS's P/E ratio is 44.54. In terms of profitability, HCG.BO's ROE is +0.02%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, HCG.BO is less volatile compared to JLHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check JLHL.NS's competition here
HCG.BO vs JLHL.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, JLHL.BO has a market cap of 83.5B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while JLHL.BO trades at ₹1,273.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas JLHL.BO's P/E ratio is 44.10. In terms of profitability, HCG.BO's ROE is +0.02%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, HCG.BO is less volatile compared to JLHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check JLHL.BO's competition here
HCG.BO vs HCG.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, HCG.NS has a market cap of 82.4B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while HCG.NS trades at ₹584.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas HCG.NS's P/E ratio is 433.11. In terms of profitability, HCG.BO's ROE is +0.02%, compared to HCG.NS's ROE of +0.02%. Regarding short-term risk, HCG.BO is less volatile compared to HCG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check HCG.NS's competition here
HCG.BO vs YATHARTH.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, YATHARTH.BO has a market cap of 67.9B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while YATHARTH.BO trades at ₹704.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas YATHARTH.BO's P/E ratio is 40.43. In terms of profitability, HCG.BO's ROE is +0.02%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check YATHARTH.BO's competition here
HCG.BO vs YATHARTH.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, YATHARTH.NS has a market cap of 67.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while YATHARTH.NS trades at ₹704.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas YATHARTH.NS's P/E ratio is 40.40. In terms of profitability, HCG.BO's ROE is +0.02%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check YATHARTH.NS's competition here
HCG.BO vs KOVAI.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, KOVAI.BO has a market cap of 56.1B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while KOVAI.BO trades at ₹5,125.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas KOVAI.BO's P/E ratio is 23.80. In terms of profitability, HCG.BO's ROE is +0.02%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, HCG.BO is less volatile compared to KOVAI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KOVAI.BO's competition here
HCG.BO vs INDRAMEDCO.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, INDRAMEDCO.BO has a market cap of 36.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while INDRAMEDCO.BO trades at ₹401.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas INDRAMEDCO.BO's P/E ratio is 20.13. In terms of profitability, HCG.BO's ROE is +0.02%, compared to INDRAMEDCO.BO's ROE of +0.31%. Regarding short-term risk, HCG.BO is less volatile compared to INDRAMEDCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check INDRAMEDCO.BO's competition here
HCG.BO vs INDRAMEDCO.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, INDRAMEDCO.NS has a market cap of 36.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while INDRAMEDCO.NS trades at ₹401.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas INDRAMEDCO.NS's P/E ratio is 20.12. In terms of profitability, HCG.BO's ROE is +0.02%, compared to INDRAMEDCO.NS's ROE of +0.31%. Regarding short-term risk, HCG.BO is less volatile compared to INDRAMEDCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check INDRAMEDCO.NS's competition here
HCG.BO vs ARTEMISMED.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, ARTEMISMED.BO has a market cap of 36.8B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while ARTEMISMED.BO trades at ₹232.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, HCG.BO's ROE is +0.02%, compared to ARTEMISMED.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to ARTEMISMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ARTEMISMED.BO's competition here
HCG.BO vs ARTEMISMED.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, ARTEMISMED.NS has a market cap of 36.5B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while ARTEMISMED.NS trades at ₹231.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas ARTEMISMED.NS's P/E ratio is 101.13. In terms of profitability, HCG.BO's ROE is +0.02%, compared to ARTEMISMED.NS's ROE of +0.11%. Regarding short-term risk, HCG.BO is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ARTEMISMED.NS's competition here
HCG.BO vs KOVAI.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, KOVAI.NS has a market cap of 35.3B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while KOVAI.NS trades at ₹2,581.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas KOVAI.NS's P/E ratio is 20.74. In terms of profitability, HCG.BO's ROE is +0.02%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, HCG.BO is less volatile compared to KOVAI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KOVAI.NS's competition here
HCG.BO vs DRAGARWQ.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, DRAGARWQ.BO has a market cap of 21.9B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while DRAGARWQ.BO trades at ₹4,661.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas DRAGARWQ.BO's P/E ratio is 31.58. In terms of profitability, HCG.BO's ROE is +0.02%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, HCG.BO is less volatile compared to DRAGARWQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check DRAGARWQ.BO's competition here
HCG.BO vs SHALBY.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, SHALBY.BO has a market cap of 16.3B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while SHALBY.BO trades at ₹152.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas SHALBY.BO's P/E ratio is 194.94. In terms of profitability, HCG.BO's ROE is +0.02%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to SHALBY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check SHALBY.BO's competition here
HCG.BO vs SHALBY.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, SHALBY.NS has a market cap of 16.3B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while SHALBY.NS trades at ₹151.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas SHALBY.NS's P/E ratio is 194.74. In terms of profitability, HCG.BO's ROE is +0.02%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check SHALBY.NS's competition here
HCG.BO vs KMCSHIL.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, KMCSHIL.BO has a market cap of 13.7B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while KMCSHIL.BO trades at ₹84.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas KMCSHIL.BO's P/E ratio is 37.57. In terms of profitability, HCG.BO's ROE is +0.02%, compared to KMCSHIL.BO's ROE of +0.22%. Regarding short-term risk, HCG.BO is less volatile compared to KMCSHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check KMCSHIL.BO's competition here
HCG.BO vs MAXINDIA.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, HCG.BO's ROE is +0.02%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to MAXINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MAXINDIA.BO's competition here
HCG.BO vs MAXIND.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, MAXIND.NS has a market cap of 8.2B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while MAXIND.NS trades at ₹155.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas MAXIND.NS's P/E ratio is -5.23. In terms of profitability, HCG.BO's ROE is +0.02%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, HCG.BO is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MAXIND.NS's competition here
HCG.BO vs ASARFI.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, ASARFI.BO has a market cap of 3.2B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while ASARFI.BO trades at ₹163.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas ASARFI.BO's P/E ratio is 19.64. In terms of profitability, HCG.BO's ROE is +0.02%, compared to ASARFI.BO's ROE of +0.14%. Regarding short-term risk, HCG.BO is more volatile compared to ASARFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check ASARFI.BO's competition here
HCG.BO vs LOTUSEYE.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, LOTUSEYE.BO has a market cap of 2.3B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while LOTUSEYE.BO trades at ₹108.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas LOTUSEYE.BO's P/E ratio is 339.38. In terms of profitability, HCG.BO's ROE is +0.02%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check LOTUSEYE.BO's competition here
HCG.BO vs LOTUSEYE.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, LOTUSEYE.NS has a market cap of 2.3B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while LOTUSEYE.NS trades at ₹108.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas LOTUSEYE.NS's P/E ratio is 338.16. In terms of profitability, HCG.BO's ROE is +0.02%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to LOTUSEYE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check LOTUSEYE.NS's competition here
HCG.BO vs AASHKA.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, AASHKA.BO has a market cap of 1.9B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while AASHKA.BO trades at ₹76.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas AASHKA.BO's P/E ratio is 76.92. In terms of profitability, HCG.BO's ROE is +0.02%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, HCG.BO is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check AASHKA.BO's competition here
HCG.BO vs LEHIL.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, HCG.BO's ROE is +0.02%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check LEHIL.BO's competition here
HCG.BO vs JSTL.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, JSTL.BO has a market cap of 1B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while JSTL.BO trades at ₹65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas JSTL.BO's P/E ratio is -51.40. In terms of profitability, HCG.BO's ROE is +0.02%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, HCG.BO is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check JSTL.BO's competition here
HCG.BO vs FORTISMLR.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, FORTISMLR.BO has a market cap of 1B. Regarding current trading prices, HCG.BO is priced at ₹584.50, while FORTISMLR.BO trades at ₹53.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas FORTISMLR.BO's P/E ratio is 22.12. In terms of profitability, HCG.BO's ROE is +0.02%, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, HCG.BO is less volatile compared to FORTISMLR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check FORTISMLR.BO's competition here
HCG.BO vs ASPIRA.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, ASPIRA.BO has a market cap of 626.8M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while ASPIRA.BO trades at ₹60.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas ASPIRA.BO's P/E ratio is 44.13. In terms of profitability, HCG.BO's ROE is +0.02%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, HCG.BO is more volatile compared to ASPIRA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check ASPIRA.BO's competition here
HCG.BO vs NGIND.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, NGIND.BO has a market cap of 476.9M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while NGIND.BO trades at ₹135.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas NGIND.BO's P/E ratio is 9.74. In terms of profitability, HCG.BO's ROE is +0.02%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, HCG.BO is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check NGIND.BO's competition here
HCG.BO vs MEDINOV.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, HCG.BO's ROE is +0.02%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, HCG.BO is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check MEDINOV.BO's competition here
HCG.BO vs CMMHOSP.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, CMMHOSP.BO has a market cap of 297M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while CMMHOSP.BO trades at ₹39.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas CMMHOSP.BO's P/E ratio is -32.59. In terms of profitability, HCG.BO's ROE is +0.02%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, HCG.BO is less volatile compared to CMMHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check CMMHOSP.BO's competition here
HCG.BO vs TEJNAKSH.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, TEJNAKSH.BO has a market cap of 271.8M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while TEJNAKSH.BO trades at ₹13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas TEJNAKSH.BO's P/E ratio is 19.68. In terms of profitability, HCG.BO's ROE is +0.02%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, HCG.BO is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check TEJNAKSH.BO's competition here
HCG.BO vs SML.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, SML.BO has a market cap of 254.1M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while SML.BO trades at ₹59.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas SML.BO's P/E ratio is -25.46. In terms of profitability, HCG.BO's ROE is +0.02%, compared to SML.BO's ROE of -1.02%. Regarding short-term risk, HCG.BO is more volatile compared to SML.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check SML.BO's competition here
HCG.BO vs KKSHL.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, KKSHL.BO has a market cap of 245.1M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while KKSHL.BO trades at ₹36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas KKSHL.BO's P/E ratio is -23.84. In terms of profitability, HCG.BO's ROE is +0.02%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, HCG.BO is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.BO.Check KKSHL.BO's competition here
HCG.BO vs GLHRL.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, GLHRL.BO has a market cap of 180.7M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while GLHRL.BO trades at ₹17.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas GLHRL.BO's P/E ratio is -7.65. In terms of profitability, HCG.BO's ROE is +0.02%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to GLHRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check GLHRL.BO's competition here
HCG.BO vs FAMILYCARE.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, FAMILYCARE.BO has a market cap of 177.7M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while FAMILYCARE.BO trades at ₹3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas FAMILYCARE.BO's P/E ratio is -3.39. In terms of profitability, HCG.BO's ROE is +0.02%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, HCG.BO is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check FAMILYCARE.BO's competition here
HCG.BO vs LOOKS.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, LOOKS.BO has a market cap of 110.5M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while LOOKS.BO trades at ₹10.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas LOOKS.BO's P/E ratio is 52.60. In terms of profitability, HCG.BO's ROE is +0.02%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to LOOKS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check LOOKS.BO's competition here
HCG.BO vs ZDHJERK.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, ZDHJERK.BO has a market cap of 103.2M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while ZDHJERK.BO trades at ₹25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas ZDHJERK.BO's P/E ratio is 39.34. In terms of profitability, HCG.BO's ROE is +0.02%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, HCG.BO is less volatile compared to ZDHJERK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check ZDHJERK.BO's competition here
HCG.BO vs GIANLIFE.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, GIANLIFE.BO has a market cap of 87.1M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while GIANLIFE.BO trades at ₹8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas GIANLIFE.BO's P/E ratio is -12.03. In terms of profitability, HCG.BO's ROE is +0.02%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, HCG.BO is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check GIANLIFE.BO's competition here
HCG.BO vs DLCL.BO Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, DLCL.BO has a market cap of 72.4M. Regarding current trading prices, HCG.BO is priced at ₹584.50, while DLCL.BO trades at ₹16.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas DLCL.BO's P/E ratio is 21.70. In terms of profitability, HCG.BO's ROE is +0.02%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, HCG.BO is less volatile compared to DLCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check DLCL.BO's competition here
HCG.BO vs NEPHROCARE-ST.NS Comparison February 2026
HCG.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.BO stands at 82.4B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, HCG.BO is priced at ₹584.50, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.BO currently has a P/E ratio of 432.96, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, HCG.BO's ROE is +0.02%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, HCG.BO is less volatile compared to NEPHROCARE-ST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.BO.Check NEPHROCARE-ST.NS's competition here